(12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery

Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 – 2 SUBTITLE: An initial report from the Vall d’Hebron COVID-19 prospective cohort 3 study.

https://doi.org/10.1101/2020.05.07.20094599

This preliminary report from the Vall d’Hebron COVID-19 Prospective Cohort Study describes the characteristics and clinical outcomes of patients who were hospitalized in non-ICU wards and received treatment with tocilizumab. Their results show that a timely administration of immune-modulating therapies, before the onset of respiratory insufficiency or ARDS, can improve severe COVID-19 patients’ outcomes with a threefold reduction in 7-day mortality.